American pharmaceutical company. Its products range from covid-19 vaccines to Viagra. In 2025 Pfizer reported declining sales and earnings, and won a bidding war with Novo Nordisk over Metsera, a developer of anti-obesity drugs, raising its offer from $7bn to $10bn. The same year Pfizer agreed to pay $1.25bn in fees to 3SBio, a Chinese biotech firm, for the rights to manufacture and sell an experimental cancer drug outside China, if approved.
The "cutting edge" is getting rather dull.